With nearly 300 bsAb programs in development worldwide, the pressure to find stable, SC-ready formulations is growing. This webinar introduces the unique challenges of formulating bispecific antibodies and why standard mAb approaches often fail. We highlight how molecular properties—such as linkers, hydrophobic patches, and charge profiles—drive instability and manufacturability risks.

The session shows how data-driven tools, molecular modeling, and smart formulation strategies enable faster, more robust development of high-concentration and SC-ready bsAb drug products.

Key Takeways:
- Understand why bsAbs require different formulation strategies than mAbs.
- Learn the main molecular drivers of aggregation, viscosity, and degradation.
- See how pH, excipients, and RoA influence bsAb stability.
- Discover how data science and ExPreSo™ accelerate formulation decisions.
- Gain practical guidance for designing stable, high-concentration bsAb formulations early.